Clinical profiles of 15 patients with ITP at blood sampling
| PT no. . | Age, y . | Sex . | Plt count, ×103/μL . | Medications . | Splenectomy . | Duration of ITP . |
|---|---|---|---|---|---|---|
| 1 | 71 | F | 189-311 | P | No | 1 mo |
| 2 | 63 | F | 14-212 | SB+P | Yes | > 10 y |
| 3 | 37 | F | 5-199 | SB+P | Yes | > 10 y |
| 5 | 65 | F | 64-116 | P | No | 6-10 y |
| 6 | 49 | F | 189 | P | No | 1 mo |
| 7* | 55 | M | 103-105 | N | Yes | > 10 y |
| 12* | 56 | F | 22-116 | SB+P | Yes | > 10 y |
| 17 | 64 | F | 23-146 | SB+P | Yes | > 10 y |
| 23 | 75 | F | 41-97 | N | No | 1-5 y |
| 34 | 67 | M | 17-144 | P | No | 4-8 mo |
| 36 | 72 | F | 76-186 | P+IV | No | 1-3 mo |
| 37 | 62 | F | 27 | P | Yes | > 10 y |
| 41 | 53 | F | 40-55 | SB+P | Yes | > 10 y |
| 42 | 42 | F | 128-271 | SB | Yes | > 10 y |
| 45 | 73 | F | 17-203 | P+IV | No | 3-7 mo |
| PT no. . | Age, y . | Sex . | Plt count, ×103/μL . | Medications . | Splenectomy . | Duration of ITP . |
|---|---|---|---|---|---|---|
| 1 | 71 | F | 189-311 | P | No | 1 mo |
| 2 | 63 | F | 14-212 | SB+P | Yes | > 10 y |
| 3 | 37 | F | 5-199 | SB+P | Yes | > 10 y |
| 5 | 65 | F | 64-116 | P | No | 6-10 y |
| 6 | 49 | F | 189 | P | No | 1 mo |
| 7* | 55 | M | 103-105 | N | Yes | > 10 y |
| 12* | 56 | F | 22-116 | SB+P | Yes | > 10 y |
| 17 | 64 | F | 23-146 | SB+P | Yes | > 10 y |
| 23 | 75 | F | 41-97 | N | No | 1-5 y |
| 34 | 67 | M | 17-144 | P | No | 4-8 mo |
| 36 | 72 | F | 76-186 | P+IV | No | 1-3 mo |
| 37 | 62 | F | 27 | P | Yes | > 10 y |
| 41 | 53 | F | 40-55 | SB+P | Yes | > 10 y |
| 42 | 42 | F | 128-271 | SB | Yes | > 10 y |
| 45 | 73 | F | 17-203 | P+IV | No | 3-7 mo |
Plt indicates platelet; P, prednisolone; SB, eltrombopag; N, none, and IV, intravenous gamma globulin.
PTs 7 and 12 were studied in our previous reports as nos. 2 and 6, respectively.15